Adipocyte Mineralocorticoid Receptor Activation Leads to Metabolic Syndrome and Induction of Prostaglandin D2 Synthase.
Identifieur interne : 000770 ( Main/Exploration ); précédent : 000769; suivant : 000771Adipocyte Mineralocorticoid Receptor Activation Leads to Metabolic Syndrome and Induction of Prostaglandin D2 Synthase.
Auteurs : Riccardo Urbanet ; Aurelie Nguyen Dinh Cat ; Alessandra Feraco ; Nicolas Venteclef ; Soumaya El Mogrhabi ; Catalina Sierra-Ramos ; Diego Alvarez De La Rosa ; Gail K. Adler ; Didier Quilliot ; Patrick Rossignol ; Francesco Fallo ; Rhian M. Touyz ; Frédéric Jaisser [France]Source :
- Hypertension [ 1524-4563 ] ; 2015.
Descripteurs français
- KwdFr :
- ARN messager (biosynthèse), ARN messager (génétique), Adipocytes blancs, Aldostérone (pharmacologie), Animaux, Antagonistes des récepteurs des minéralocorticoïdes (pharmacologie), Antagonistes des récepteurs des minéralocorticoïdes (usage thérapeutique), Cellules 3T3-L1, Dibenzocycloheptènes (pharmacologie), Graisse intra-abdominale (anatomopathologie), Graisse intra-abdominale (métabolisme), Graisse intra-abdominale (physiopathologie), Graisse sous-cutanée (métabolisme), Humains, Induction enzymatique (), Insulinorésistance, Intramolecular oxidoreductases (biosynthèse), Intramolecular oxidoreductases (génétique), Lignée cellulaire tumorale, Lipocalines (biosynthèse), Lipocalines (génétique), Mâle, Obésité (génétique), Obésité (physiopathologie), Pipéridines (pharmacologie), Récepteurs des minéralocorticoïdes (biosynthèse), Récepteurs des minéralocorticoïdes (génétique), Récepteurs des minéralocorticoïdes (physiologie), Récepteurs à la leptine (déficit), Régulation positive, Souris, Souris obèse, Souris transgéniques, Spironolactone (pharmacologie), Spironolactone (usage thérapeutique), Syndrome métabolique X (physiopathologie), Syndrome métabolique X (traitement médicamenteux), Syndrome métabolique X (étiologie).
- MESH :
- anatomopathologie : Graisse intra-abdominale.
- biosynthèse : ARN messager, Intramolecular oxidoreductases, Lipocalines, Récepteurs des minéralocorticoïdes.
- déficit : Récepteurs à la leptine.
- génétique : ARN messager, Intramolecular oxidoreductases, Lipocalines, Obésité, Récepteurs des minéralocorticoïdes.
- métabolisme : Graisse intra-abdominale, Graisse sous-cutanée.
- pharmacologie : Aldostérone, Antagonistes des récepteurs des minéralocorticoïdes, Dibenzocycloheptènes, Pipéridines, Spironolactone.
- physiologie : Récepteurs des minéralocorticoïdes.
- physiopathologie : Graisse intra-abdominale, Obésité, Syndrome métabolique X.
- traitement médicamenteux : Syndrome métabolique X.
- usage thérapeutique : Antagonistes des récepteurs des minéralocorticoïdes, Spironolactone.
- étiologie : Syndrome métabolique X.
- Adipocytes blancs, Animaux, Cellules 3T3-L1, Humains, Induction enzymatique, Insulinorésistance, Lignée cellulaire tumorale, Mâle, Régulation positive, Souris, Souris obèse, Souris transgéniques.
English descriptors
- KwdEn :
- 3T3-L1 Cells, Adipocytes, White, Aldosterone (pharmacology), Animals, Cell Line, Tumor, Dibenzocycloheptenes (pharmacology), Enzyme Induction (drug effects), Humans, Insulin Resistance, Intra-Abdominal Fat (metabolism), Intra-Abdominal Fat (pathology), Intra-Abdominal Fat (physiopathology), Intramolecular Oxidoreductases (biosynthesis), Intramolecular Oxidoreductases (genetics), Lipocalins (biosynthesis), Lipocalins (genetics), Male, Metabolic Syndrome X (drug therapy), Metabolic Syndrome X (etiology), Metabolic Syndrome X (physiopathology), Mice, Mice, Obese, Mice, Transgenic, Mineralocorticoid Receptor Antagonists (pharmacology), Mineralocorticoid Receptor Antagonists (therapeutic use), Obesity (genetics), Obesity (physiopathology), Piperidines (pharmacology), RNA, Messenger (biosynthesis), RNA, Messenger (genetics), Receptors, Leptin (deficiency), Receptors, Mineralocorticoid (biosynthesis), Receptors, Mineralocorticoid (genetics), Receptors, Mineralocorticoid (physiology), Spironolactone (pharmacology), Spironolactone (therapeutic use), Subcutaneous Fat (metabolism), Up-Regulation.
- MESH :
- chemical , biosynthesis : Intramolecular Oxidoreductases, Lipocalins, RNA, Messenger, Receptors, Mineralocorticoid.
- chemical , deficiency : Receptors, Leptin.
- chemical , genetics : Intramolecular Oxidoreductases, Lipocalins, RNA, Messenger, Receptors, Mineralocorticoid.
- chemical , pharmacology : Aldosterone, Dibenzocycloheptenes, Mineralocorticoid Receptor Antagonists, Piperidines, Spironolactone.
- drug effects : Enzyme Induction.
- drug therapy : Metabolic Syndrome X.
- etiology : Metabolic Syndrome X.
- genetics : Obesity.
- metabolism : Intra-Abdominal Fat, Subcutaneous Fat.
- pathology : Intra-Abdominal Fat.
- chemical , physiology : Receptors, Mineralocorticoid.
- physiopathology : Intra-Abdominal Fat, Metabolic Syndrome X, Obesity.
- chemical , therapeutic use : Mineralocorticoid Receptor Antagonists, Spironolactone.
- 3T3-L1 Cells, Adipocytes, White, Animals, Cell Line, Tumor, Humans, Insulin Resistance, Male, Mice, Mice, Obese, Mice, Transgenic, Up-Regulation.
Abstract
Metabolic syndrome is a major risk factor for the development of diabetes mellitus and cardiovascular diseases. Pharmacological antagonism of the mineralocorticoid receptor (MR), a ligand-activated transcription factor, limits metabolic syndrome in preclinical models, but mechanistic studies are lacking to delineate the role of MR activation in adipose tissue. In this study, we report that MR expression is increased in visceral adipose tissue in a preclinical mouse model of metabolic syndrome and in obese patients. In vivo conditional upregulation of MR in mouse adipocytes led to increased weight and fat mass, insulin resistance, and metabolic syndrome features without affecting blood pressure. We identified prostaglandin D2 synthase as a novel MR target gene in adipocytes and AT56, a specific inhibitor of prostaglandin D2 synthase enzymatic activity, blunted adipogenic aldosterone effects. Moreover, translational studies showed that expression of MR and prostaglandin D2 synthase is strongly correlated in adipose tissues from obese patients.
DOI: 10.1161/HYPERTENSIONAHA.114.04981
PubMed: 25966493
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000054
- to stream PubMed, to step Curation: 000054
- to stream PubMed, to step Checkpoint: 000059
- to stream Ncbi, to step Merge: 000189
- to stream Ncbi, to step Curation: 000182
- to stream Ncbi, to step Checkpoint: 000182
- to stream Main, to step Merge: 000759
- to stream Main, to step Curation: 000770
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adipocyte Mineralocorticoid Receptor Activation Leads to Metabolic Syndrome and Induction of Prostaglandin D2 Synthase.</title><author><name sortKey="Urbanet, Riccardo" sort="Urbanet, Riccardo" uniqKey="Urbanet R" first="Riccardo" last="Urbanet">Riccardo Urbanet</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="Nguyen Dinh Cat, Aurelie" sort="Nguyen Dinh Cat, Aurelie" uniqKey="Nguyen Dinh Cat A" first="Aurelie" last="Nguyen Dinh Cat">Aurelie Nguyen Dinh Cat</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="Feraco, Alessandra" sort="Feraco, Alessandra" uniqKey="Feraco A" first="Alessandra" last="Feraco">Alessandra Feraco</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="Venteclef, Nicolas" sort="Venteclef, Nicolas" uniqKey="Venteclef N" first="Nicolas" last="Venteclef">Nicolas Venteclef</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="El Mogrhabi, Soumaya" sort="El Mogrhabi, Soumaya" uniqKey="El Mogrhabi S" first="Soumaya" last="El Mogrhabi">Soumaya El Mogrhabi</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="Sierra Ramos, Catalina" sort="Sierra Ramos, Catalina" uniqKey="Sierra Ramos C" first="Catalina" last="Sierra-Ramos">Catalina Sierra-Ramos</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="Alvarez De La Rosa, Diego" sort="Alvarez De La Rosa, Diego" uniqKey="Alvarez De La Rosa D" first="Diego" last="Alvarez De La Rosa">Diego Alvarez De La Rosa</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="Adler, Gail K" sort="Adler, Gail K" uniqKey="Adler G" first="Gail K" last="Adler">Gail K. Adler</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="Quilliot, Didier" sort="Quilliot, Didier" uniqKey="Quilliot D" first="Didier" last="Quilliot">Didier Quilliot</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="Rossignol, Patrick" sort="Rossignol, Patrick" uniqKey="Rossignol P" first="Patrick" last="Rossignol">Patrick Rossignol</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="Fallo, Francesco" sort="Fallo, Francesco" uniqKey="Fallo F" first="Francesco" last="Fallo">Francesco Fallo</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="Touyz, Rhian M" sort="Touyz, Rhian M" uniqKey="Touyz R" first="Rhian M" last="Touyz">Rhian M. Touyz</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="Jaisser, Frederic" sort="Jaisser, Frederic" uniqKey="Jaisser F" first="Frédéric" last="Jaisser">Frédéric Jaisser</name><affiliation wicri:level="1"><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.). frederic.jaisser@inserm.fr.</nlm:affiliation><country wicri:rule="url">France</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25966493</idno><idno type="pmid">25966493</idno><idno type="doi">10.1161/HYPERTENSIONAHA.114.04981</idno><idno type="wicri:Area/PubMed/Corpus">000054</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000054</idno><idno type="wicri:Area/PubMed/Curation">000054</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000054</idno><idno type="wicri:Area/PubMed/Checkpoint">000059</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000059</idno><idno type="wicri:Area/Ncbi/Merge">000189</idno><idno type="wicri:Area/Ncbi/Curation">000182</idno><idno type="wicri:Area/Ncbi/Checkpoint">000182</idno><idno type="wicri:Area/Main/Merge">000759</idno><idno type="wicri:Area/Main/Curation">000770</idno><idno type="wicri:Area/Main/Exploration">000770</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Adipocyte Mineralocorticoid Receptor Activation Leads to Metabolic Syndrome and Induction of Prostaglandin D2 Synthase.</title><author><name sortKey="Urbanet, Riccardo" sort="Urbanet, Riccardo" uniqKey="Urbanet R" first="Riccardo" last="Urbanet">Riccardo Urbanet</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="Nguyen Dinh Cat, Aurelie" sort="Nguyen Dinh Cat, Aurelie" uniqKey="Nguyen Dinh Cat A" first="Aurelie" last="Nguyen Dinh Cat">Aurelie Nguyen Dinh Cat</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="Feraco, Alessandra" sort="Feraco, Alessandra" uniqKey="Feraco A" first="Alessandra" last="Feraco">Alessandra Feraco</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="Venteclef, Nicolas" sort="Venteclef, Nicolas" uniqKey="Venteclef N" first="Nicolas" last="Venteclef">Nicolas Venteclef</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="El Mogrhabi, Soumaya" sort="El Mogrhabi, Soumaya" uniqKey="El Mogrhabi S" first="Soumaya" last="El Mogrhabi">Soumaya El Mogrhabi</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="Sierra Ramos, Catalina" sort="Sierra Ramos, Catalina" uniqKey="Sierra Ramos C" first="Catalina" last="Sierra-Ramos">Catalina Sierra-Ramos</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="Alvarez De La Rosa, Diego" sort="Alvarez De La Rosa, Diego" uniqKey="Alvarez De La Rosa D" first="Diego" last="Alvarez De La Rosa">Diego Alvarez De La Rosa</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="Adler, Gail K" sort="Adler, Gail K" uniqKey="Adler G" first="Gail K" last="Adler">Gail K. Adler</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="Quilliot, Didier" sort="Quilliot, Didier" uniqKey="Quilliot D" first="Didier" last="Quilliot">Didier Quilliot</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="Rossignol, Patrick" sort="Rossignol, Patrick" uniqKey="Rossignol P" first="Patrick" last="Rossignol">Patrick Rossignol</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="Fallo, Francesco" sort="Fallo, Francesco" uniqKey="Fallo F" first="Francesco" last="Fallo">Francesco Fallo</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="Touyz, Rhian M" sort="Touyz, Rhian M" uniqKey="Touyz R" first="Rhian M" last="Touyz">Rhian M. Touyz</name><affiliation><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.).</nlm:affiliation><wicri:noCountry code="subField">F.J.).</wicri:noCountry></affiliation></author><author><name sortKey="Jaisser, Frederic" sort="Jaisser, Frederic" uniqKey="Jaisser F" first="Frédéric" last="Jaisser">Frédéric Jaisser</name><affiliation wicri:level="1"><nlm:affiliation>From the INSERM, UMR_S 1138, Teams 1 (R.U., A.F., S.E.M., F.J.) and 8 (N.V.), Centre de Recherche des Cordeliers, UPMC Univ Paris 06, Université Paris Descartes, Paris, France; Department of Medicine (DIMED), University of Padova, Padova, Italy (R.U., F.F.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.N.D.C., R.M.T.); Laboratory of Cardiovascular Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy (A.F.); Department of Physiology and Institute of Biomedical Technologies, University of La Laguna, Tenerife, Spain (D.A.D.l.R.); Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.); Department of Nutrition, Nancy University Hospital, INSERM U954, Medical Faculty and CHU of Nancy, Vandoeuvre-les-Nancy, France (D.Q.); and INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, and Université de Lorraine, and Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT) French Clinical Research Infrastructure Network (F-CRIN), Nancy, France (P.R., F.J.). frederic.jaisser@inserm.fr.</nlm:affiliation><country wicri:rule="url">France</country></affiliation></author></analytic><series><title level="j">Hypertension</title><idno type="eISSN">1524-4563</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>3T3-L1 Cells</term><term>Adipocytes, White</term><term>Aldosterone (pharmacology)</term><term>Animals</term><term>Cell Line, Tumor</term><term>Dibenzocycloheptenes (pharmacology)</term><term>Enzyme Induction (drug effects)</term><term>Humans</term><term>Insulin Resistance</term><term>Intra-Abdominal Fat (metabolism)</term><term>Intra-Abdominal Fat (pathology)</term><term>Intra-Abdominal Fat (physiopathology)</term><term>Intramolecular Oxidoreductases (biosynthesis)</term><term>Intramolecular Oxidoreductases (genetics)</term><term>Lipocalins (biosynthesis)</term><term>Lipocalins (genetics)</term><term>Male</term><term>Metabolic Syndrome X (drug therapy)</term><term>Metabolic Syndrome X (etiology)</term><term>Metabolic Syndrome X (physiopathology)</term><term>Mice</term><term>Mice, Obese</term><term>Mice, Transgenic</term><term>Mineralocorticoid Receptor Antagonists (pharmacology)</term><term>Mineralocorticoid Receptor Antagonists (therapeutic use)</term><term>Obesity (genetics)</term><term>Obesity (physiopathology)</term><term>Piperidines (pharmacology)</term><term>RNA, Messenger (biosynthesis)</term><term>RNA, Messenger (genetics)</term><term>Receptors, Leptin (deficiency)</term><term>Receptors, Mineralocorticoid (biosynthesis)</term><term>Receptors, Mineralocorticoid (genetics)</term><term>Receptors, Mineralocorticoid (physiology)</term><term>Spironolactone (pharmacology)</term><term>Spironolactone (therapeutic use)</term><term>Subcutaneous Fat (metabolism)</term><term>Up-Regulation</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ARN messager (biosynthèse)</term><term>ARN messager (génétique)</term><term>Adipocytes blancs</term><term>Aldostérone (pharmacologie)</term><term>Animaux</term><term>Antagonistes des récepteurs des minéralocorticoïdes (pharmacologie)</term><term>Antagonistes des récepteurs des minéralocorticoïdes (usage thérapeutique)</term><term>Cellules 3T3-L1</term><term>Dibenzocycloheptènes (pharmacologie)</term><term>Graisse intra-abdominale (anatomopathologie)</term><term>Graisse intra-abdominale (métabolisme)</term><term>Graisse intra-abdominale (physiopathologie)</term><term>Graisse sous-cutanée (métabolisme)</term><term>Humains</term><term>Induction enzymatique ()</term><term>Insulinorésistance</term><term>Intramolecular oxidoreductases (biosynthèse)</term><term>Intramolecular oxidoreductases (génétique)</term><term>Lignée cellulaire tumorale</term><term>Lipocalines (biosynthèse)</term><term>Lipocalines (génétique)</term><term>Mâle</term><term>Obésité (génétique)</term><term>Obésité (physiopathologie)</term><term>Pipéridines (pharmacologie)</term><term>Récepteurs des minéralocorticoïdes (biosynthèse)</term><term>Récepteurs des minéralocorticoïdes (génétique)</term><term>Récepteurs des minéralocorticoïdes (physiologie)</term><term>Récepteurs à la leptine (déficit)</term><term>Régulation positive</term><term>Souris</term><term>Souris obèse</term><term>Souris transgéniques</term><term>Spironolactone (pharmacologie)</term><term>Spironolactone (usage thérapeutique)</term><term>Syndrome métabolique X (physiopathologie)</term><term>Syndrome métabolique X (traitement médicamenteux)</term><term>Syndrome métabolique X (étiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Intramolecular Oxidoreductases</term><term>Lipocalins</term><term>RNA, Messenger</term><term>Receptors, Mineralocorticoid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="deficiency" xml:lang="en"><term>Receptors, Leptin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Intramolecular Oxidoreductases</term><term>Lipocalins</term><term>RNA, Messenger</term><term>Receptors, Mineralocorticoid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Aldosterone</term><term>Dibenzocycloheptenes</term><term>Mineralocorticoid Receptor Antagonists</term><term>Piperidines</term><term>Spironolactone</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Graisse intra-abdominale</term></keywords><keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>ARN messager</term><term>Intramolecular oxidoreductases</term><term>Lipocalines</term><term>Récepteurs des minéralocorticoïdes</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Enzyme Induction</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Metabolic Syndrome X</term></keywords><keywords scheme="MESH" qualifier="déficit" xml:lang="fr"><term>Récepteurs à la leptine</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Metabolic Syndrome X</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Obesity</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>ARN messager</term><term>Intramolecular oxidoreductases</term><term>Lipocalines</term><term>Obésité</term><term>Récepteurs des minéralocorticoïdes</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Intra-Abdominal Fat</term><term>Subcutaneous Fat</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Graisse intra-abdominale</term><term>Graisse sous-cutanée</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Intra-Abdominal Fat</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Aldostérone</term><term>Antagonistes des récepteurs des minéralocorticoïdes</term><term>Dibenzocycloheptènes</term><term>Pipéridines</term><term>Spironolactone</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Récepteurs des minéralocorticoïdes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Receptors, Mineralocorticoid</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Graisse intra-abdominale</term><term>Obésité</term><term>Syndrome métabolique X</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Intra-Abdominal Fat</term><term>Metabolic Syndrome X</term><term>Obesity</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Mineralocorticoid Receptor Antagonists</term><term>Spironolactone</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome métabolique X</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antagonistes des récepteurs des minéralocorticoïdes</term><term>Spironolactone</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Syndrome métabolique X</term></keywords><keywords scheme="MESH" xml:lang="en"><term>3T3-L1 Cells</term><term>Adipocytes, White</term><term>Animals</term><term>Cell Line, Tumor</term><term>Humans</term><term>Insulin Resistance</term><term>Male</term><term>Mice</term><term>Mice, Obese</term><term>Mice, Transgenic</term><term>Up-Regulation</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adipocytes blancs</term><term>Animaux</term><term>Cellules 3T3-L1</term><term>Humains</term><term>Induction enzymatique</term><term>Insulinorésistance</term><term>Lignée cellulaire tumorale</term><term>Mâle</term><term>Régulation positive</term><term>Souris</term><term>Souris obèse</term><term>Souris transgéniques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Metabolic syndrome is a major risk factor for the development of diabetes mellitus and cardiovascular diseases. Pharmacological antagonism of the mineralocorticoid receptor (MR), a ligand-activated transcription factor, limits metabolic syndrome in preclinical models, but mechanistic studies are lacking to delineate the role of MR activation in adipose tissue. In this study, we report that MR expression is increased in visceral adipose tissue in a preclinical mouse model of metabolic syndrome and in obese patients. In vivo conditional upregulation of MR in mouse adipocytes led to increased weight and fat mass, insulin resistance, and metabolic syndrome features without affecting blood pressure. We identified prostaglandin D2 synthase as a novel MR target gene in adipocytes and AT56, a specific inhibitor of prostaglandin D2 synthase enzymatic activity, blunted adipogenic aldosterone effects. Moreover, translational studies showed that expression of MR and prostaglandin D2 synthase is strongly correlated in adipose tissues from obese patients.</div></front></TEI><affiliations><list><country><li>France</li></country></list><tree><noCountry><name sortKey="Adler, Gail K" sort="Adler, Gail K" uniqKey="Adler G" first="Gail K" last="Adler">Gail K. Adler</name><name sortKey="Alvarez De La Rosa, Diego" sort="Alvarez De La Rosa, Diego" uniqKey="Alvarez De La Rosa D" first="Diego" last="Alvarez De La Rosa">Diego Alvarez De La Rosa</name><name sortKey="El Mogrhabi, Soumaya" sort="El Mogrhabi, Soumaya" uniqKey="El Mogrhabi S" first="Soumaya" last="El Mogrhabi">Soumaya El Mogrhabi</name><name sortKey="Fallo, Francesco" sort="Fallo, Francesco" uniqKey="Fallo F" first="Francesco" last="Fallo">Francesco Fallo</name><name sortKey="Feraco, Alessandra" sort="Feraco, Alessandra" uniqKey="Feraco A" first="Alessandra" last="Feraco">Alessandra Feraco</name><name sortKey="Nguyen Dinh Cat, Aurelie" sort="Nguyen Dinh Cat, Aurelie" uniqKey="Nguyen Dinh Cat A" first="Aurelie" last="Nguyen Dinh Cat">Aurelie Nguyen Dinh Cat</name><name sortKey="Quilliot, Didier" sort="Quilliot, Didier" uniqKey="Quilliot D" first="Didier" last="Quilliot">Didier Quilliot</name><name sortKey="Rossignol, Patrick" sort="Rossignol, Patrick" uniqKey="Rossignol P" first="Patrick" last="Rossignol">Patrick Rossignol</name><name sortKey="Sierra Ramos, Catalina" sort="Sierra Ramos, Catalina" uniqKey="Sierra Ramos C" first="Catalina" last="Sierra-Ramos">Catalina Sierra-Ramos</name><name sortKey="Touyz, Rhian M" sort="Touyz, Rhian M" uniqKey="Touyz R" first="Rhian M" last="Touyz">Rhian M. Touyz</name><name sortKey="Urbanet, Riccardo" sort="Urbanet, Riccardo" uniqKey="Urbanet R" first="Riccardo" last="Urbanet">Riccardo Urbanet</name><name sortKey="Venteclef, Nicolas" sort="Venteclef, Nicolas" uniqKey="Venteclef N" first="Nicolas" last="Venteclef">Nicolas Venteclef</name></noCountry><country name="France"><noRegion><name sortKey="Jaisser, Frederic" sort="Jaisser, Frederic" uniqKey="Jaisser F" first="Frédéric" last="Jaisser">Frédéric Jaisser</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Lorraine/explor/InforLorV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000770 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000770 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Lorraine
|area= InforLorV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25966493
|texte= Adipocyte Mineralocorticoid Receptor Activation Leads to Metabolic Syndrome and Induction of Prostaglandin D2 Synthase.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25966493" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a InforLorV4
| This area was generated with Dilib version V0.6.33. |  |